uniQure N.V. (QURE) Stock Analysis
$QURE · Healthcare · Biotechnology
uniQure (QURE), a Biotechnology company, has a market capitalization of about $956.7M.
Price
$15.53
Market cap
$956.7M
Dividend yield
—
About uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
How StockWorthy values QURE
StockWorthy forecasts uniQure N.V.'s revenue, operating profitability, reinvestment (capital expenditure, depreciation and working capital) and unlevered free cash flow, then discounts those cash flows using a normalized cost of capital built from QURE's size, profitability and balance-sheet risk. Terminal growth is adjusted to reflect the company's mature growth profile rather than a fixed number. The model presents bear, base and bull scenarios, and every key assumption stays transparent and adjustable in the full StockWorthy analysis. Results are educational and not investment advice.
Related stocks
See QURE's Fair Value
Create a free account to view uniQure N.V.'s base-case fair value, the bear–bull modeled range, and every assumption behind them. Free accounts include 5 stock valuations per month — plus Advanced DCF models, financial charts, dividends, and peer analysis.